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ABSTRACT 
 
 
Toll like receptor (TLR)s have a central role in regulating innate immunity and in the last 
decade studies have begun to reveal their significance in potentiating autoimmune 
diseases such as rheumatoid arthritis (RA). Earlier investigations have highlighted the 
importance of TLR2 and TLR4 function in RA pathogenesis. In this review, we discuss 
the newer data that indicate roles for TLR5 and TLR7 in RA and its preclinical models. 
We evaluate the pathogenicity of TLRs in RA myeloid cells, synovial tissue fibroblasts, 
T cells, osteoclast progenitor cells and endothelial cells. These observations establish that 
ligation of TLRs can transform RA myeloid cells into M1 macrophages and that the 
inflammatory factors secreted from M1 and RA synovial tissue fibroblasts participate in 
TH-17 cell development. From the investigations conducted in RA preclinical models, 
we conclude that TLR-mediated inflammation can result in osteoclastic bone erosion by 
interconnecting the myeloid and TH-17 cell response to joint vascularization. In light of 
emerging unique aspects of TLR function, we summarize the novel approaches that are 
being tested to impair TLR activation in RA patients.      
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INTRODUCTION 
 
Prevalent in 1% of the population, rheumatoid arthritis (RA) is one of the most common 
autoimmune disorders [1]. RA is characterized by persistent inflammation driven by the 
proliferating synovial tissue fibroblasts as well as T and B cells, neutrophils and 
monocytes trafficking into the joint [2, 3]. Cells invading the RA pannus express 
proinflammatory cytokines, chemokines and matrix metalloproteinases that contribute to 
progressive cartilage and bone destruction [3-5].  
 
The etiopathology of RA is not fully defined; however several genetic and environmental 
factors have been implicated  [6]. Genetic loci associated with RA susceptibility include 
HLA-DR4, PTPN22, PADI4, STAT4, CTLA4, TNF, IL-1 and IL-18. The major 
environmental factor that augments risk for and severity of RA is smoking, especially in 
HLA-DRB1 patients, with possible additional roles for infection and tissue injury. Toll 
like receptors (TLR)s are the front line sensors of danger signals that are released 
following  injury or infection, and by pathogens [7] (Fig. 1).  
 
The functions of TLR2 and TLR4 have been extensively studied in RA through use of in 
vitro systems and experimental models [8-11], however more recent studies have also 
revealed a significant impact of TLR5 and TLR7 in RA pathology [12-16]. Depending on 
localization and distribution patterns of TLRs and their associated signaling pathways in 
RA patients, various TLR family members are important in different stages of disease [8-
11]. Herein, we review the most recent advances concerning the importance of TLR 
function in RA with a specific focus on TLR5 and TLR7 in RA and in animal models of 
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RA. Furthermore, we summarize potential therapeutic approaches targeting TLRs, their 
endogenous ligands and the signaling pathways associated with these receptors (Fig. 2). 
 
1. TLR expression pattern, their corresponding exogenous and endogenous ligands 
as well as TLR association with RA pathology  
 
TLRs represent a family of pattern recognition receptors and to date 10 subtypes have 
been identified in human (TLR1-10) and 12 in mouse (TLR1-9, TLR11-13). TLRs are 
classified based on their cellular localization and ligand selection. TLRs 1, 2, 4, 5 and 6 
are expressed on the cell surface and recognize microbial components, whereas, 
endosomal TLRs 3, 7, 8 and 9 mainly detect nucleic acids [17] (Fig. 2 and Table 1). 
 
Cell surface TLRs 
1.1 TLR1 
TLR1 is anchored in the plasma membrane and it predominately forms a heterodimer 
with TLR2 (Fig. 2). The TLR1/TLR2 complex recognizes tri-acetylated lipopeptides 
coupled to peptidoglycan (PGN) [18]. TLR1 is expressed on leukocytes such as 
monocytes, macrophages, B and T cells, dendritic cells (DC)s, NK cells,  
polymorphonuclear cells (PMN)s as well as non-immune cells including RA fibroblasts, 
keratinocytes and epithelial cells [19].  
 
1.2 TLR2 and TLR4 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
5 
 
TLR2 recognizes a wide range of ligands through heterodimers that it forms with TLR1 
and TLR6 [20], and possibly TLR10 (Fig. 2). In contrast, TLR4 typically binds to its 
corresponding ligand as a homodimer, although in some exceptional cases TLR4 forms a 
dimer with TLR5 [21, 22]. Several Pathogen-Associated Molecular Patterns (PAMPs), 
such as lipoarabinomannan (LAM), LPS, lipoteichoic acid (LTA), PGN, and other 
glycolipids, glycoproteins, and lipoproteins, are activators of TLR2  [23-27]. Moreover, 
TLR2 heterodimers are recognized by viral envelope proteins of measles virus (MV), 
human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV1) and hepatitis C 
virus (HCV), fungal  zymosan and some protozoa [25, 28-30]. However, TLR4 is 
activated by LPS, as well as fungal mannan and glucuronoxylmannan [30]. Furthermore, 
the TLR4 dimer can be activated by envelope proteins of respiratory syncytial virus 
(RSV), HCV, and mouse mammary tumor virus (MMTV)[30]. In addition, damage-
associated molecular patterns (DAMPs) activate TLR2 and TLR4 signaling. Heat shock 
protein (HSP) 60 and 70, biglycan, GP96, high mobility group box (HMGB)1, Surfactant 
protein A/D and HA fragments are endogenous ligands that are capable of TLR2 and 
TLR4 ligation [31-36]. Recent studies demonstrate that DAMPs utilize unique 
combination of co-receptors and accessory proteins, therefore TLR activation and 
function may vary depending on DAMP or PAMP binding.  
 
In line with elevated levels of endogenous ligands, TLR2 and TLR4 are highly expressed 
by RA synovial tissue (ST) lining macrophages and fibroblasts and sublining 
macrophages [36, 37]. In vitro studies confirmed the expression of TLR2 and TLR4 on 
RA peripheral blood (PB) monocytes, macrophages differentiated from PB and synovial 
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fluid (SF) monocytes and RA ST fibroblasts [36-38]. Although, TLR2 and TLR4 
function has been implicated in RA pathogenesis, there is conflicting information 
regarding association of single nucleotide polymorphisms (SNP)s of TLR2 and TLR4  
with severity of RA  [39, 40].  
 
1.3 TLR5 
Prior to 2012, very little was known about the role of TLR5 in RA. TLR5 binds as a 
monomer to flagellin and recent studies document that TLR5 endogenous ligands are 
present in RA SF [12-14], although the identity of these natural ligands remain unknown. 
TLR5 expression is accentuated in RA compared to normal (NL) lining fibroblasts and 
macrophages and sublining macrophages and endothelial cells [14]. In RA PB monocytes 
and  in vitro differentiated macrophages expression levels of TLR5 are increased by TNF 
and IL-17 respectively; whereas various monokines and RA SF can upregulate TLR5 on 
RA ST fibroblasts [14]. Notably, myeloid TLR5 expression positively correlates with RA 
disease activity (DAS28) and with TNF levels, supporting its role in RA pathology [14].        
 
1.4 TLR6 
TLR6 heterodimerizes with TLR2, and hence binds to the same exogenous ligands and 
some of the TLR2 endogenous ligands [11, 20]. Although TLR1, TLR2 and TLR6 have 
similar expression patterns, expression of TLR1 and TLR6 is more prominent than TLR2 
on B cells [41]. Nevertheless, the impact of TLR6 is undefined in RA. 
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Endosomal TLRs 
1.5 TLR3 
TLR3 is different from the other family members, as it does not signal via MyD88, but 
instead exclusively activates TIR-domain-containing adapter-inducing interferon-β 
(TRIF) [42, 43]. The expression of TLR3 was determined, by some groups, to be 
restricted to DCs, however others reported that TLR3 is expressed by T cells, NK cells, 
granulocytes and monocytes [44-46]. TLR3 forms a homodimer and is activated by viral 
double stranded (ds) RNA which suggests that the dsRNA released from necrotic cells in 
the RA SF is the TLR3 endogenous ligand [47]. Previous studies showed that a TLR3 
(rs3775291) SNP is associated with DAS28 and swollen joint counts in the Danish sero-
negative RA population [48]. In contrast, no correlation was detected between the TLR3 
(rs3775290) SNP and RA susceptibility factor in the Turkish population [49]. In RA 
synovial tissue (ST), joint fibroblasts express elevated levels of TLR3 at the early stage 
of disease [34]. Others demonstrate that TLR3 is equally expressed by RA and NL 
monocytes, and interferon (IFN) is capable of elevating TLR3 expression levels on both 
RA myeloid cells and ST fibroblasts [50, 51]. Supporting this notion, the expression 
patterns of TLR3 and IFN are closely correlated in RA ST [50, 51]. When RA and NL 
myeloid cells were stimulated by a TLR3 agonist, the inflammatory response was similar 
in both healthy and RA cells [51]. Altogether, the literature suggests that the pathogenic 
effect of TLR3 is due to its differential expression in RA compared to NL fibroblasts and 
its presence on myeloid cells is less significant for disease progression.     
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1.6 TLR7 and TLR8 
Both TLR7 and TLR8 recognize ssRNA [16], however recent findings document that 
these receptors bind to specific RNA sequences [15]. While TLR7 binds to GU-rich 
oligos, TLR8 tends to ligate to AU-rich domain [52, 53]. Corroborating these findings, 
we showed that although both TLR7/8 can recognize ssRNA extracted from RA SF [16], 
the GU-rich micro RNA (miR)-Let7b released from RA SF macrophages has a unique 
ability to bind to TLR7 and is not recognized by TLR8 [15]. It was demonstrated that 
RNA from RA SF, but not RA or NL plasma, could induce TNF transcription from RA 
monocytes. Consistently, inhibition of myeloid TLR7 ligation or degradation of ssRNA 
suppresses SF induced TNF transcription, establishing that TLR7 endogenous ligands are 
enriched in RA SF [16].  Both in RA blood and SF, miR-Let7b is primarily released from 
macrophages and it is secreted at lower levels from blood T cells and neutrophils as well 
as from RA ST fibroblasts [15]. To date, the TLR8 endogenous ligand has not been 
identified.   
 
TLR7 and TLR8 are predominately expressed by RA ST lining and sublining 
macrophages as well as by  RA ST lining fibroblasts [16]. Nevertheless, their expression 
is differentially regulated in RA myeloid cells [16]. While expression of TLR7 is 
enhanced by IL-17 and IL-8; LPS and IL-1 are responsible for increasing the TLR8 levels 
in RA monocytes and macrophages [16]. Interestingly, expression of TLR7 in RA 
monocytes correlates with DAS28 and TNF levels. By contrast, expression of TLR8 in 
RA myeloid cells does not correlate with DAS28, TLR7 or TNF levels [15].  
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1.7 TLR9 
TLR9 recognizes internalized bacterial DNA and non-methylated CpG oligonucleotides 
[54, 55]. Ribosomal DNA containing non-methylated CpG repeats, released from the 
dead cells in the RA serum, can potentially be a TLR9 endogenous ligand [54, 55]. TLR9 
is expressed by B cells and it operates synergistically with the B cell receptor complex to 
release rheumatoid factor (RF) [56]. Additionally, ligation of TLR9 by CpG promotes B 
cell class switch from IgM to a more pathogenic IgG isotype [57]. TLR9 is elevated in 
RA compared to osteoarthritis (OA) ST fibroblasts and its expression is augmented by 
hypoxia in RA ST fibroblasts [58]. Moreover, RA patients with active disease expressed 
markedly higher levels of TLR9 in PB monocytes and SF macrophages compared to NL 
counterpart cells [59].  A correlation was found between a TLR9 (rs187084) SNP and RA 
susceptibility in the Turkish population [49]. 
 
1.8 TLR10 
TLR10 is expressed on human but not in murine immune cells, with the highest levels in 
B cells [41, 44]. TLR10 forms a heterodimer with TLR2 and is therefore responsive to 
TLR2-binding P MPs [23, 26]. Little is known about TLR10 endogenous ligands and 
function, but a recent study reported that TLR10 is induced following influenza virus 
infection and it may play a role in the innate immune responses to the influenza virus 
[60]. In contrast, others found that TLR10 may serve as an anti-inflammatory receptor by 
reducing proinflammatory cytokine production by human PBMCs [61]. Consistent with 
the previous findings, TLR10 knockdown elevated cytokine release from human myeloid 
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cells. Correspondingly, mice overexpressing human TLR10 demonstrated a significantly 
lower inflammatory response when injected with the TLR2 ligand, Pam3CSK4 [61].  
 
Taken together, RA macrophages and ST fibroblasts are the effector cells that play an 
integral role in TLR-mediated inflammatory mechanisms that are relevant to arthritis. In 
subsequent sections, we will review the mechanisms by which TLR ligation impacts RA 
synovial lining cells as well as the other cell types that are involved in the pathogenesis of 
RA.   
 
2. Mechanisms of TLR function 
 Biological agents that have been approved for RA therapy include antibodies that target 
TNF or IL-6 activity as well as therapeutics that block T cell function or deplete B cells. 
Yet, there are subsets of RA patients that do not respond to the aforementioned strategies. 
Therefore the need persists for novel therapeutic approaches that are more effective and 
less expensive. To understand the significant importance of TLR function in RA, we 
focus on RA cells that highly express these receptors and are therefore responsive to their 
corresponding exogenous and endogenous ligands. We will also discuss the cells that are 
indirectly impacted by TLR activation in the RA joint. 
 
2.1 Macrophages: Monocytes migrate from blood into the inflamed RA joint where they 
differentiate into macrophages. Macrophages are categorized into M1 and M2 subsets. 
M1 macrophages are the classically activated cells that produce proinflammatory 
cytokines, which mediate resistance to pathogens and provoke tissue damage. M2 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
11 
 
macrophages are the alternatively activated cells which secrete anti-inflammatory factors 
participating in tissue restoration [62, 63]. As previously described, TLR2, TLR4, TLR5, 
TLR7 and TLR8 are highly expressed by  RA PB monocytes, ST and SF macrophages, 
and ligation by their exogenous and endogenous ligands promotes inflammatory response 
[11, 35, 37, 64].  
 
2.1.1 TLR2 and TLR4 
In RA monocytes and ST macrophages, TLR2 expression levels were elevated by 
macrophage colony stimulating factor (M-CSF) and IL-10 treatment [37]. In contrast, 
while IL-10 had no effect on myeloid TLR4 concentration, transforming growth factor 
(TGF)-1 had a suppressive effect on TLR4 levels [65]. Others have shown that the M1 
driving factor, IFN-, increases monocyte response to LPS by upregulating TLR4 surface 
expression [66]. Interestingly, sex hormones have a differential impact on TLR4 levels.   
Estrogen upregulates myeloid cell surface TLR4 expression, whilst testosterone reduces 
the receptor level on macrophages [67, 68].      
 
Earlier studies demonstrated that RA PB and SF myeloid cells are responsive to TLR2 
and TLR4 microbial ligands. More recent studies determined that HSP60 and GP96 
binding to TLR2 and/or TLR4 can elicit similar inflammatory response [37, 69]. On the 
contrary, release of miR-155 from macrophages during inflammation can restrict the 
secretion of inflammatory cytokines during the late phase of TLR4 ligation in these cells 
[70]. Notably, in NL PB in vitro differentiated macrophages and RA SF macrophages, 
GP96 stimulation markedly accentuates TLR2 expression, while this natural ligand has 
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an inverse effect on TLR4 levels in NL PB myeloid cells [10, 69], suggesting that TLR2 
and TLR4 are differentially modulated in myeloid cells.   
 
2.1.2 TLR5 
We have shown that ligation of exogenous as well as endogenous TLR5 ligands 
expressed in RA SF can transform naive RA myeloid cells into proinflammatory M1 
macrophages [14]. Additionally, TNF produced from M1 macrophages can synergize 
with the TLR5 agonist, flagellin, to promote monocyte chemotaxis [12]. Consistently, 
blockade of TLR5 on myeloid cells and neutralization of TNF in RA SF can more 
potently suppress RA SF driven monocyte infiltration compared to inhibition of each 
cascade alone [14]. We further document a cross talk between TLR5 and TNF pathways, 
as patients on the combination of disease-modifying anti-rheumatic drugs (DMARD)s 
and anti-TNF antibody treatment demonstrated markedly lower myeloid TLR5 
expression compared to those treated only with DMARDs [14].  
 
 
2.1.3 TLR7 and TLR8 
Binding of the TLR7 and TLR8 agonist, R848, to RA monocytes and macrophages 
induces TNF and CCL21 production [16]. Interestingly, it is shown while expression of 
TLR7 closely associates with TNF transcription levels in RA monocytes, the 
concentration of TLR8 does not correspond to TLR7 or TNF expression [16]. The SF 
ssRNA that binds to RA TLR7+ myeloid cells, is a GUUGUGU rich miR-Let7b that is 
predominately packaged in exosomes of RA SF macrophages [15]. Knockdown of TLR7 
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but not TLR8 suppressed the miR-Let7b-mediated inflammatory response in myeloid 
cells [15]. Induction of cell death in RA SF macrophages can further amplify the 
discharge of the exosomal miR-Let7b into the SF [15].  Similar  to  the  M1 macrophage 
positive controls, IFNγ and LPS, miR-Let7b  can  remodel  the  RA  naïve  myeloid  cell  
into  M1 macrophages  that express  elevated  levels of  iNOS  and CD127 [15].  The M1 
differentiation  process is driven  by  miR-Let7b  through  TLR7  ligation,  given  that  
the  use  of  TLR7  antagonists or  TLR7  knockout  mice  impairs  this  process  [15]. 
Consistent with this notion, we reported that exosomes containing miR-Let7b are fully 
functional and can transform mouse naïve (M0) or anti-inflammatory (M2) macrophages 
into inflammatory M1 macrophages [15].    
 
In short, evidence from our lab and other groups, highlights that ligation of myeloid 
TLR2, TLR4, TLR5 and TLR7 by their natural ligands expressed in RA SF can remodel 
naïve cells into proinflammatory M1 macrophages.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 
2.2 RA ST fibroblasts: The hyperplastic RA lining layer consists of RA fibroblasts and 
macrophages which expand from 1-3 layers to 10-15 cell layers in the inflamed joints 
[71]. Neovascularization of RA synovium triggered by pro-angiogenic growth factors 
released from fibroblasts can further potentiate inflammation via increased leukocyte 
infiltration [63, 72]. It is known that fibroblasts within the RA hyperplastic ST overgrow 
the underlying cartilage surface and subsequently invade cartilage and bone to promote 
joint destruction [71, 73]. Factors secreted into RA SF as a result of joint destruction or 
cell death can serve as TLR natural ligands.   
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TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9 are expressed by RA ST fibroblasts. TLR2 
expression on RA ST fibroblasts is modulated by TNF, IL-1, LPS and miR-19 [34, 35, 
37, 74-77]. While  IL-17  upregulates expression of TLR2, TLR3 and TLR4 on RA ST 
fibroblasts [78], proinflammatory factors such as TNF-α, ΙL-1β, IL-17, IL-6, IL-8 and RA 
SF could greatly elevate TLR5 expression in RA fibroblasts [14]. Despite the higher 
expression of TLR7 in RA compared to NL fibroblasts, unlike TLR5, its expression was 
not affected when cells were stimulated with LPS, TNF-α, IL-1β, IL-17, IL-6, IL-8 or RA 
SF [16]. Unlike TLR7, expression of TLR8 was undetectable in RA or NL ST fibroblasts 
[16]. Low levels of TLR9 were detected in RA ST fibroblasts which were not inducible 
by activation with CpG ODNs [58, 79].    
 
TLR2 ligation in RA ST fibroblasts enhances secretion of proinflammatory cytokines 
(IL-6, CCL8), proangiogenic factors (VEGF, IL-8, CXCL2) adhesion molecules (ICAM-
1) and matrix metalloproteinases (MMPs1/3/13) [37]. In RA ST fibroblasts, TLR2 and 
TLR4 ligation can synergistically contribute to IL-15 production [74]. Hypoxia 
potentiates TLR2-, TLR3- and TLR9-driven IL-6 and IL-8 transcription from RA ST 
fibroblasts. In contrast, TLR4-induced IL-6 and IL-8 expression is suppressed by hypoxia 
in these cells [58]. IL-29 also accentuates TLR2, TLR3 and TLR4 mediated IL-6 and IL-
8 production from RA ST fibroblasts [80]. Moreover, receptor activator for nuclear factor 
B ligand (RANKL), MMP1 and MMP2 were released from TLR2, TLR3 and TLR4 
activated RA ST fibroblasts [81]. Binding of synthetic TLR3 ligand as well as stimulation 
with necrotic SF cells promotes production of IFN- from RA ST fibroblasts which is 
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known to impair osteoclast differentiation [47]. Ligation of TLR5 by flagellin can dose 
responsively secrete IL-6 and CCL2 from RA ST fibroblasts [14]. 
 
In the RA pannus, fibroblasts are in direct contact with macrophages, T cells and vascular 
endothelial cells. Consequently, factors produced from fibroblasts under stress, hypoxia 
or inflammation can trigger further pathological changes in these neighboring cells.  
 
2.3 Osteoclast maturation: Osteoclasts are multinucleated bone-eroding cells that 
differentiate from the myeloid cells found in RA PB or ST. RA joint macrophages 
cultured in presence of inflammatory cytokines or RA SF differentiate into mature 
osteoclasts. Osteoclast formation is mediated through ligation of myeloid receptor 
activator for nuclear factor B (RANK) to its ligand, RANKL, produced from RA ST 
fibroblasts and T cells [2, 82-85].  
 
 
2.3.1 TLR2, 3, 4 and 9 
Earlier studies demonstrate that TLR2 and TLR4 exogenous ligands cooperate with IFN-
 in suppressing RANK and M-CSR receptor expression, thus impairing osteoclast 
maturation [86]. Others observed that ligands for TLR2, 3, 4 and 9 had an inhibitory 
effect on osteoclast differentiation by reducing the production of RANKL [87]. A 
different study documented that osteoclastogenesis is impaired by IL-12 produced from 
TLR9 stimulated osteoclast precursor cells [88]. Despite the inhibitory effect of TLR2 
and TLR4 on osteoclastogenesis, once osteoclasts are formed, ligation of TLR2 and 
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TLR4 enhances the survival of the differentiated cells [87]. In contrast to in vitro studies, 
results from experimental arthritis models support a role of TLR4 in arthritic bone 
destruction [89, 90].  
 
2.3.2 TLR5 
 The TLR5 agonist, flagellin, dose-dependently promotes osteoclast maturation, both 
through its direct effect on myeloid cell function and indirectly via TNF production from 
RA and mouse myeloid cells [12, 14]. Consistent with findings in RA, TLR5 ligation 
strongly transforms mouse bone marrow progenitor cells into mature osteoclasts through 
a TNF-dependent and IFN-β-independent mechanism [12]. A potent positive feedback 
regulation has been described between TLR5 and TNF cascades in recruiting circulating 
monocytes into the inflamed joints and further remodeling the newly infiltrated cells into 
mature osteoclasts [12]. 
 
2.3.3 TLR7/8  
The TLR7- and TLR8-binding oligo, R848, was shown to dose responsively negate 
RANKL induced osteoclast differentiation in NL PB myeloid cells as well as in mouse 
bone marrow progenitor cells through a mechanism that was partially due to IFN-
induction [91]. However, once mouse bone marrow osteoclasts were fully matured, 
R848 treatment had no impact on osteoclast survival or their bone-resorbing activity [91]. 
The data from the literature suggests that TLR ligands can differentially impact RA 
osteoclastic bone erosion and their maintenance depending on the osteoclast maturation 
stage.  
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2.4 T cell function: We and others have shown that there is a dominance of TH-17 cells 
in RA PB and SF compared to normal individuals [92-95]. In RA patients, the balance 
between TH-17 cells and T regulatory cells T(reg)s is dysregulated and Tregs have 
reduced suppressive activity [96, 97]. TLRs are known to have an integral role in T cell 
differentiation and function.    
 
Previous studies reported that conditioned media obtained from human PBMCs 
stimulated with TLR4 and TLR7/8 agonists, but not from those activated with TLR2, 3 
and 9 agonists, promoted TH-17 cell differentiation [98] (Fig. 3). Interestingly, binding of 
myeloid related protein (MRP)8 expressed in RA SF to TLR4 in PBMCs induces TH-17 
polarization [99, 100]. Consistently, IL-6 produced from RA ST fibroblasts, activated by 
MRP8, was capable of transforming naïve CD4+ T cells into TH-17 cells [101] (Fig. 3). 
Others have shown that activation of TLR4 and TLR9 but not TLR2, in B and T cell co-
cultures markedly increases expression of retinoic acid related orphan receptor (RORC) 
and IL-17 [102].  Confirming this notion, it was shown that the Treg cell population was 
reduced in TLR2-/- compared to wild type mice, as TLR2 ligands, unlike TLR4 and 
TLR9 agonists, augmented Treg proliferation [103]. As such, the spontaneous arthritis 
detected in IL-1 receptor antagonist knockout (IL1rn-/-) was more severe when these 
mice were backcrossed into a TLR2-/- background, and the clinical manifestations were 
markedly reduced when IL1rn-/- were crossed with TLR4-/- mice [104]. Notably 
activation of human PBMCs activated with TLR7s agonist potentiates TH-1 and TH-17 
cell differentiation [105].   
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 TLR4 can affect T cell adherence and migration since human T cells adhere to 
fibronectin via TLR4 binding, and a TLR4 agonist inhibits CXCL12 mediated T cell 
chemotaxis [105]. In addition to APC-provoked T cell activation, some TLRs such as 
TLR2, 3, 5, 7 and 9 are expressed on T cells and can directly impact T cell function. T 
cells activated with a TLR3 agonist, secrete IL-17 and IL-21, and these TLR3-driven IL-
21-producing cells express CXCR3, which can further contribute to T cell trafficking into 
the joint [106].   
 
Most recently it was shown that ligation of TLR5 in RA PBMCs can promote TH-17 cell 
polarization via myeloid cell production of IL-6 and IL-1[13]. IL-17 produced by the 
TLR5 activated PBMCs was capable of inducing endothelial cell migration. IL-17-driven 
angiogenesis could further potentiate TLR5 mediated inflammation and osteoclastic bone 
erosion [13] (Fig. 3).      
 
Thus ligation of TLRs shifts the balance towards TH-17 cell polarization via mechanisms 
that in part depend on proinflammatory cytokines secreted from M1 macrophages and 
RA ST fibroblasts (Fig. 3). 
 
2.5 Angiogenesis and endothelial cell function: Angiogenesis is an early and critical 
event in RA that promotes leukocyte infiltration and pannus formation [107-109]. 
Angiogenesis encompasses complex events that impact endothelial cell function, such as 
activation, proliferation, sprouting and finally blood vessel stabilization. Stimuli known 
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to activate endothelial cells and initiate angiogenesis include hypoxia, inflammatory 
mediators and mechanical stress [63].  
  
Activation of TLRs in macrophages and RA ST fibroblasts indirectly promotes 
angiogenesis [63]. An adenosine (A)2AR agonist synergizes with TLR2, 4, 7 and 9 
ligands to increase production of vascular endothelial growth factor (VEGF) from 
macrophages [110]. In contrast, a TLR3 agonist inhibits VEGF production from 
macrophages [110]. Interesting, the natural ligand for TLR2 and TLR4, HMGB1, 
promotes secretion of proangiogenic factors from macrophages and RA ST fibroblasts to 
induce tube formation in a TLR4 dependent manner [111, 112]. Moreover, RA ST 
fibroblasts or explants stimulated with TLR2 agonists release elevated levels of VEGF, 
IL-8 and Ang-2 that can indirectly contribute to neovascularization [113, 114]. When 
naïve cells differentiate into M1 macrophages upon TLR4 activation, the released 
inflammatory factors such as TNF, IL-6, IL-1 and IL-8 can directly trigger angiogenesis 
(TNF and IL-8) or stimulate RA ST fibroblasts to produce higher levels of pro-
angiogenic factors [115]. 
 
Of note, TLR5 is one of the few TLRs that are expressed on RA ST endothelial cells 
[14]. Hence ligation of endothelial cell TLR5 by flagellin or TLR5 natural ligands 
expressed in RA SF elicits endothelial migration and tube formation. TLR5 can also 
potentiate its angiogenic effect by promoting differentiation of TH-17 cells in RA 
PBMCs [13] (Fig. 3).  
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These results from our group and others show that, with the exception of TLR5 that is 
uniquely expressed on endothelial cells and can directly affect their function, other TLRs 
affect RA angiogenesis by augmenting the production of proangiogenic factors from 
macrophages and RA ST fibroblasts. 
 
 
 
3. Impact of TLRs in preclinical models of RA 
 
A number of approaches have been utilized in acute and chronic RA preclinical models to 
evaluate the potential role of TLRs in RA pathology.  
 
3.1 Role of TLR2 and TLR4 activation in preclinical RA models: Streptococcal cell 
wall (SCW) induced arthritis was markedly reduced in TLR2-/- mice, in part due to 
decreased CCL3, CCL5 and CXCL1 levels that are responsible for infiltration of 
inflammatory cells into the arthritic joint [116]. Interestingly, TLR2 dependency was 
shifted to TLR4 dependency, when SCW was repeatedly injected in TLR2-/- mice over a 
longer time frame [117]. In the chronic model of SCW, TLR4 deficiency resulted in 
impaired osteoclast formation as well as reduction in TH-17 inducing cytokines such as 
IL-1, IL-6 and IL-23 [117]. Hence arthritic TLR4-/- mice produced lower levels of IL-17 
with no change in IFN- compared to wild type mice [117]. Consistent with these 
observations, TLR4 antagonism ameliorated clinical and histological manifestations of 
collagen induced arthritis (CIA) through downregulation of joint IL-1 levels [118]. 
Additionally a TLR4 antagonist prevented the spontaneous arthritis in IL-1Ra-/- mice 
[118]. Interestingly, joint swelling was detected in IL-1-/- mice when LPS was co-
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administered in the  serum transfer K/BxN  arthritis model, suggesting that joint 
inflammation provoked via TLR4 can bypass IL-1  [119].  
 
3.2 Impact of TLR5 ligation in RA murine models: Recent studies in CIA demonstrate 
that local administration of a TLR5 agonist exacerbates joint inflammation and bone 
erosion. This TLR5 driven inflammation is due to M1 macrophage differentiation which 
leads to release of IL-6 and IL-1 that can further stimulate TH-17 cell development [13, 
14]. Elevated levels of IL-17 provoked by TLR5 ligation in CIA joints is involved in 
arthritic neovascularization [13]. Conversely, anti-TLR5 antibody treatment reduces M1 
macrophage and TH-17 cell polarization [12]. Notably, TLR5 mediated osteoclastic bone 
erosion is in part due to induction of TNF [12]. As blockade of both TLR5 and TNF has a 
greater ability to abrogate RA SF mediated osteoclastogenesis than blockade of each 
pathway alone [12]. Local injection of flagellin, establishes that TLR5 promotes joint 
inflammation and arthritic bone loss by linking the myeloid (TNF) and T (IL-17) arms of 
the disease [12].        
 
 
3.3 Significance of TLR3 and TLR9 function in experimental arthritis models:  
Ectopic dsRNA ligation to TLR3 promotes joint inflammation through IL-1 activation, 
since dsRNA induced arthritis is diminished in the IL-1R-/- mouse [120]. Consistent with 
this observation, K/BxN serum transfer arthritis was markedly reduced in TLR3-/- mice 
through a mechanism that was partially due to interferon regulatory factor (IRF)5 
signaling [121].  
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In contrast, systemic administration of a TLR3 agonist in collagen antibody induced 
arthritis (CAIA) alleviated arthritis by increasing type I interferons that inhibited synovial 
cell proliferation and inflammatory responses [122]. Likewise, co-administration of CpG 
ODNs (TLR9 agonist) together with K/BxN serum resolved joint inflammation by 
potentiating IL-12 and IFN-production and inhibiting synovial neutrophil infiltration 
[123].   
 
3.4 Implication of TLR7 signaling in RA preclinical models: In rat CIA, pre-onset 
treatment with short hairpin TLR7-binding RNA ameliorated arthritis due to reduction in 
joint micro-vessel density and VEGF release from fibroblasts [124]. Others documented 
that CIA was alleviated in TLR7-/- mice, due to the suppression of the IL-17 response 
and elevation of joint Tregs [125]. Similarly, in the K/BxN serum transfer arthritis model, 
joint inflammation was attenuated in TLR7-/- compared to wild type mice in part due to  
reduced serum levels of IL-1, CXCL1, CXCL10 and CCL3 [121].  
 
Our group was the first to report that miR-Let7b, predominately packaged in RA SF 
exosomes, is an endogenous ligand for TLR7 [15]. We documented that ligation of TLR7 
by local injection of miR-Let7b triggers joint inflammation and increased lining thickness 
in wild type mice compared to the control group. On the contrary, joint swelling was 
blunted in TLR7 deficient mice that received ectopic injection of adenovirus (Ad)-Let7b 
or Ad-Ctl, signifying that ligation of miR-Let7b to TLR7 is responsible for arthritis 
induction. We found that local injection of miR-Let7b provokes arthritic joint 
inflammation by recruiting myeloid cells from the circulation into joint and further 
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transforming them into M1 macrophages that secrete high levels of TNF, IL-1, IL-6, 
CCL2, CCL5 and express the M1 marker iNOS [15].  
 
Altogether, the data suggest that activation of TLR4, TLR5 and TLR7 has critical 
implications for joint inflammation and bone destruction observed in RA preclinical 
models. However, ligation of TLR2, TLR3 and TLR9 may have dual effects on disease 
manifestations depending on the experimental arthritis model employed.          
 
4. Therapeutic approaches targeting TLRs: 
Use of biologics has improved RA patient care, however there is a percent of patients that 
do not tolerate or respond to these therapies. Given that TLRs play an instrumental role in 
RA pathology a number of strategies have been developed to target TLR driven 
inflammatory response.  
 
These strategies include: 1) using soluble decoy receptors or neutralizing antibodies that 
block the ligand-receptor interaction, 2) impairing receptor dimerization, 3) inhibiting the 
release of endogenous ligands or the TLR expression levels and 4) suppressing TLR 
associated downstream pathways. 
 
4.1 TLR2/4 blockade: There are antagonistic antibodies generated against TLR2 and 
TLR4 which are still at the preclinical phase (reviewed in [11, 126, 127]). OPN305 
(Opsona Therapeutics),  a blocking antibody that abrogates TLR2/TLR1 and TLR2/TLR6 
activation and release of proinflammatory cytokines, is currently in the preclinical phase 
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[11]. OPN305 blockade of TLR2 activity on human monocytes was well tolerated in 
healthy individuals [128]. A different antibody, OPN301, constructed by Opsona 
therapeutics, was as effective as anti-TNF antibody in inhibiting the spontaneous 
production of proinflammatory factors from RA explants [129]. The TLR4 monoclonal 
antibody, NI0101, generated by NovImmune is in a preclinical phase [11]. NI0101 binds 
to an epitope on TLR4 and compromises its dimerization and activation. The synthetic 
Lipid A antagonist, eritoran (E5564; Eisai Pharmaceuticals), prevents LPS from binding 
to the MD2-TLR4 receptor complex [126]. Additionally, eritoran downregulates LPS 
induced cytokine production in human monocytes, the effects of LPS inhalation and 
sepsis in experimental models [130]. Eritoran is in phase III, however the compound 
needs to be administrated repeatedly to elicit a therapeutic response [126].       
 
4.2 Targeting TLR3/7/9 activation: The anti-malarial drug, choloroquine, inhibits 
lysoendosomal acidification of TLR3, 7, 8 and 9.  Consequently, choloroquine interferes 
with chemotaxis, phagocytosis and antigen presentation mediated by endosomal TLRs 
[131]. Additionally the antidepressant drugs, fluoxetine and citalopram, inhibit 
endosomal TLRs and have shown to alleviate CIA and reduce RA synovial membrane 
mediated cytokine production [132]. Currently, Idera is developing a DNA-based TLR7/9 
antagonist, IMO-3100, for RA, SLE and psoriasis treatment. The phase I studies 
demonstrated that this compound was well tolerated and decreased TNF and IL-1 
production in human donors [11]. Dynavaz is also in the process of developing a DNA 
based compound against TLR7/TLR9 (DV-1179) which is in the preclinical stage [11]. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
25 
 
4.3 Targeting endogenous ligands or reducing the synovial TLR expression levels 
Neutralizing antibody or a truncated version of HMGB1, an endogenous ligand for TLR2 
and TLR4, ameliorated CIA [133]. An inhibitor for HSP90 was also capable of resolving 
joint inflammation in rat CIA [134]. Despite findings in murine models, given that there 
are numerous TLR2 and TLR4 natural ligands detected in RA joint, blocking a single 
ligand may not efficiently suppress TLR2 and TLR4 function. Certain mi-RNAs can 
post-transcriptionally impact TLR expression, associated transcription factors and TLR 
induced cytokines. As such, it is shown that miR-21, miR-147 and miR-155 modulate 
cell surface TLR2/4 frequency and their downstream signaling mediators including NF-
kB and IRF3 [135]. In monocytes, TLR4 induced tolerance is due to release of miR-146, 
as levels of miR-146 inversely correlate with LPS induced TNF production [136].            
 
4.4 Targeting TLR downstream pathways 
A selective p38 MAPK inhibitor, papamimod, resolved clinical manifestations in an RA 
preclinical model, yet this p38 inhibitor was less efficacious than MTX [137, 138]. A 
different p38 MAPK inhibitor synthetized by GlaxoSmithKline is currently in phase I 
clinical trial [11]. MLN-0415, an IKKinhibitor developed by Millennium to target the 
NF-B pathway, was discontinued at phase I, because of its adverse effects. RDP-58, a 
decapeptide that targets IRAK complex formation, is in phase II clinical trials for Crohn’s 
disease and ulcerative colitis [139, 140].   
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5. CONCLUSIONS AND FUTURE DIRECTIONS 
It is postulated that harmful stimuli triggered by injury, infection, stress, hypoxia or cell 
death, ignite tissue damage and release of endogenous TLR ligands (Fig. 1). Binding of 
these TLR ligands to the responsive cells can lead to chronic inflammation that results in 
cartilage and bone destruction. In the last decade, evidence from RA specimen and 
preclinical models have allowed us to unravel novel endogenous ligands for TLRs and to 
gain insight into the mechanism by which binding of these natural ligands to their 
corresponding receptors promotes disease. There is no cure for RA and up to 40% of the 
heterogeneous RA patient population does not respond to anti-TNF therapies [141]. 
Circulating TH-17 cells or IL-17 levels are highly elevated subsequent to TNF blockade 
in the non-responder population [142, 143]. Ligation of TLR4, 5 and 7 has been shown to 
promote TH-17 differentiation via IL-6 and IL-1 production from M1 macrophages, 
suggesting that these receptors may play a critical role in linking the myeloid and T cell 
arms of the disease. Earlier studies have implied that targeting TLR downstream 
pathways may not be desirable because of their functional redundancy. Likewise, TLR 
natural ligands are promiscuous and each receptor may bind to various ligands. Hence 
uncovering novel strategies to halt TLR activation as well as identifying RA patients who 
will respond to these therapies are among the challenges that, if met, can ultimately 
provide more cost effective personalized care.   
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FIGURE LEGENDS 
Figure 1. Schematic figure illustrating the mechanism by which harmful stimuli can 
potentially activate release of TLR endogenous ligand that triggers TLR mediated 
inflammatory joint damage. Harmful stimuli such as injury, infection, stress and 
hypoxia promote tissue and cell death. As a result, endogenous ligands are released into 
RA synovial fluid where they can bind directly to cells that express TLRs such as RA 
macrophages, synovial tissue fibroblasts and pre-osteoclasts or affect cell (endothelial 
cells and TH-17 cell) function indirectly through production of inflammatory factors. The 
combined direct and indirect effects of TLR ligation facilitate inflammation, 
angiogenesis, TH-17 cell polarization and osteoclastic bone erosion which ultimately 
sustains the vicious cycle of inflammatory bone destruction.   
 
Figure 2. Cell surface and endosomally expressed TLRs point to potential 
therapeutic approaches targeting TLR mode of action. TLRs are classified into two 
groups based on their distribution and ligand selection. TLRs 1, 2, 4, 5 and 6 are 
expressed on the cell surface and recognize microbial components, whereas, endosomal 
TLRs 3, 7, 8 and 9 primarily detect nucleic acids. There are a number of strategies 
utilized to abrogate TLR driven inflammatory responses. These strategies include: 1) use 
of soluble decoy receptors or neutralizing antibodies that abolish the ligand and receptor 
binding, 2) suppressing the production of endogenous ligands or the TLR expression 
levels, 3) inhibiting the TLR linked downstream pathways and 4) inhibiting TLR 
expression in part through mi-RNAs. 
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Figure 3. Schematic figure illustrating the mechanism by which TLR ligands 
potentiate RA pathology. Ligation of TLR4, 5 and 7 can transform RA myeloid cells 
into M1 macrophages and as a result the inflammatory factors released from M1 and RA 
ST fibroblasts participate in TH-17 cell polarization. Ligation of TLR5 via flagellin or 
TLR5 natural ligands expressed in RA SF transforms RA myeloid cells into mature 
osteoclasts. RA osteoclastogenesis is exacerbated through joint neovascularization 
mediated directly through TLR5 ligation or indirectly via TH-17 driven angiogenesis.   
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TLR Localization Exogenous ligands Endogenous 
ligands 
Signaling 
adaptors 
Transcription 
Factors 
Cell 
Expression 
TLR1 Plasma 
membrane 
Synthetic 
triacetylated 
lipopeptide 
(Pam3CSK4), 
tri-acetylated 
lipopeptides coupled 
to peptidoglycan 
 MyD88 NF-B, AP1, 
IRF1/5/7 
Monocytes, 
Ms, B and 
T cells, NK 
cells, DCs, 
PMN, RA 
fib., RA ST 
TLR2 Plasma 
membrane 
Pam3CSK4, 
Lipoarabinomannan 
(LAM), LPS, 
lipoteichoic acid 
(LTA), PGN, and 
other glycolipids, 
glycoproteins, and 
lipoproteins 
Zymosan, protozoa 
and some viruses 
HSP60,70, 
biglycan, 
GP96, 
HMGB1, 
Surfactant 
protein A/D, 
HA 
fragment 
MyD88 NF-B, AP1, 
IRF1/5/7 
RA 
monocyes, 
RA SF 
Ms, RA 
fib., RA 
ST, and 
PBLs 
TLR4 Plasma 
membrane 
LPS, 
fungal mannan and 
glucuronoxylmannan,
protozoa, and some 
viruses 
HSP60,70, 
biglycan, 
GP96, 
HMGB1, 
Surfactant 
protein A/D, 
HA 
fragment 
Oxidized 
LDL, 
saturated 
fatty acids, 
serum 
amyloid A, 
fibronectin 
EDA, 
SS100A8/A
9 
TRIF, 
MyD88 
NF-B, AP1, 
IRF1/3/5/7 
RA mono, 
RA SF 
Ms, RA 
fib., RA 
ST, and 
PBLs 
TLR5  Plasma 
membrane 
Flagellin Ligands 
present in 
RA synovial 
fluid  
MyD88 NF-B, AP1, 
IRF1/5/7 
PBLs 
mostly 
Monocytes, 
RA SF 
Ms, RA 
fib., Endo, 
RA ST 
TLR6 Plasma 
membrane 
Pam3CSK4, diacyl 
lipopeptides, LTA, 
Versican, 
HA 
MyD88 NF-B, AP1, 
IRF1/5/7 
PBLs 
highest on 
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protozoa, and 
Zymosan 
fragments, 
PAUF 
Monocytes 
and B cells, 
Ms, RA 
fib. 
TLR3 Endosome Synthetic Poly I:C 
and Poly A:U, and 
Viral dsRNA 
RNA 
released 
from 
necrotic 
cells  
TRIF NF-B, IRF3 RA fib., 
DCs, T 
cells, 
grnaulocyte
s, and 
monocytes.  
TLR7 Endosome  Viral ssRNA, GU 
rich oligos, and 
synthetic 
imidazoquinoline 
derivatives 
RA synovial 
fluid 
ssRNA, 
miR-let7b, 
miR-29a 
MyD88 NF-B, AP1, 
IRF1/5/7 
Monocytes, 
RA SF 
Ms, RA 
fib, B cells, 
RA ST 
TLR8 Endosome Viral ssRNA, and 
synthetic 
thiazoloquinolone 
derivative (CL075) 
Not 
identified 
but probably 
RA synovial 
fluid ssRNA 
MyD88 NF-B, AP1, 
IRF1/5/7 
Monocytes, 
RA SF 
Ms, RA 
ST 
TLR9 Endosome Non methylated CpG 
bacterial DNA 
(ODN2006) 
DNA 
containing 
CpG 
ribosomal 
repeats, 
DNA- 
immune 
complexes 
(IC), IgG-
chromatin 
complexes  
MyD88 NF-B, AP1, 
IRF1/5/7 
PBLs 
highest in 
B cells and 
DCs 
TLR10 Endosome Same as TLR2 Not 
identified 
MyD88 NF-B, AP1, 
IRF1/5/7 
Expression, 
only in 
humans 
and not 
mice, on 
leukocytes 
but highest 
on B cells 
 
Table  1. The characteristics of TLRs are summarized in this table. 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
31 
 
TAKE-HOME MESSAGES 
 
 TLRs ligate to their natural ligands expressed in the RA joint to provoke joint 
inflammation and osteoclastic bone destruction 
 RA ST fibroblasts, M1 macrophages, TH-17 cells, mature osteoclasts and 
endothelial cells play critical roles in TLR-mediated RA pathology 
 Ligation of distinct TLRs can transform RA myeloid cells into M1 macrophages, 
and as a result the inflammatory factors released from M1 and RA ST fibroblasts promote   
TH-17 cell polarization 
 Specific TLR function can interconnect myeloid and the T cell arms of the disease  
 Novel approaches are being tested to target TLR function 
 
 
 
 
DISCLOSURE 
 
No conflict of interest disclosed. 
 
 
 
 
ACKNOWLEDGEMENTS 
 
This work was supported in part by awards from Department of Veteran’s Affairs 
MERIT Award 1I01BX002286, the National Institutes of Health AR056099 and 
AR065778, funding provided by Department of Defense PR093477 and Arthritis 
Foundation Innovative Research Grant. We would like to apologize to colleagues whose 
work was not cited due to space limitations. 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
32 
 
ABBREVIATIONS 
 
 
RA; rheumatoid arthritis, TLR; Toll like receptor, TH-17; T helper cells that produced 
IL-17A, DCs; dendritic cells, PMNs; poly mononuclear cells, PAMPs; pathogen-
associated molecular patterns , DAMPs; damage-associated molecular patterns, HMGB1; 
high mobility group box, HSP; heat shock protein, PB; peripheral blood, SF; synovial 
fluid, SNPs; single nucleotide polymorphisms, DAS28; RA disease activity, TRIF; TIR-
domain-containing adapter-inducing interferon-β, IFN; interferon, ST; synovial tissue, 
ssRNA; single strand RNA, dsRNA; double stand RNA; NL; normal, DMARDs; disease-
modifying anti-rheumatic drugs, RANK; receptor activator for nuclear factor B, 
RANKL, receptor activator for nuclear factor B ligand; MRP; myeloid related protein, 
ROR; retinoic acid related orphan receptor, Tregs; T regulatory cells, IL1rn-/-; IL-1 
receptor antagonist knockout, Ad; adenovirus, VEGF; vascular endothelial growth factor, 
CAIA; collagen antibody induced arthritis, CIA; collaged induced arthritis, SCW; 
streptococcal cell wall arthritis, IRF5; interferon regulatory factor 5, MMPs; matrix 
metalloproteinases, ICAM; intercellular adhesion molecule.  
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